Abeona Therapeutics Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-11$5.52 RISE2026-03-30$4.23 PEAK2026-05-06$6.01 146d | -23.4% 109d | Missed | Missed | — | — | +42.1% 37d | Missed |
DROP2025-08-22$7.23 RISE2025-11-11$4.17 PEAK2025-12-11$5.52 111d | -42.3% 81d | Missed | Missed | — | — | +32.4% 30d | Missed |
DROP2025-05-01$6.87 RISE2025-07-01$5.57 PEAK2025-08-14$7.23 105d | -18.9% 61d | Missed | Missed | — | — | +29.8% 44d | Missed |
DROP2024-11-27$6.41 RISE2025-04-10$4.18 PEAK2025-05-01$6.87 155d | -34.8% 134d | Missed | Missed | — | — | +64.4% 21d | Missed |
DROP2024-10-17$6.74 RISE2025-01-14$5.09 PEAK2025-02-14$6.02 120d | -24.5% 89d | Missed | Missed | — | — | +18.3% 31d | Missed |
DROP2024-04-03$8.05 RISE2024-08-09$4.42 PEAK2024-10-17$6.74 197d | -45.1% 128d | Missed | Missed | — | — | +52.5% 69d | Missed |
DROP2024-04-03$8.05 RISE2024-08-07$4.42 PEAK2024-10-17$6.74 197d | -45.1% 126d | Missed | Missed | — | — | +52.5% 71d | Missed |
DROP2024-03-06$8.68 RISE2024-04-24$3.17 PEAK2024-07-12$5.51 128d | -63.5% 49d | Missed | Missed | — | — | +73.8% 79d | Missed |
DROP2024-01-08$5.84 RISE2024-01-31$4.07 PEAK2024-03-06$8.68 58d | -30.3% 23d | Missed | Missed | — | — | +113.3% 35d | Missed |
DROP2023-06-22$5.27 RISE2023-10-27$3.71 PEAK2024-01-08$5.84 200d | -29.6% 127d | Missed | Missed | — | — | +57.4% 73d | Missed |
DROP2023-06-22$5.27 RISE2023-09-21$3.61 PEAK2023-11-28$4.96 159d | -31.5% 91d | Missed | Missed | — | — | +37.4% 68d | Missed |
DROP2023-06-22$5.27 RISE2023-08-08$2.98 PEAK2023-08-31$4.43 70d | -43.5% 47d | Missed | Missed | — | — | +48.7% 23d | Missed |
DROP2023-06-22$5.27 RISE2023-08-07$2.98 PEAK2023-08-31$4.43 70d | -43.5% 46d | Missed | Missed | — | — | +48.7% 24d | Missed |
DROP2022-11-01$4.90 RISE2023-02-24$2.25 PEAK2023-04-24$3.39 174d | -54.1% 115d | Missed | Missed | — | — | +50.7% 59d | Missed |
DROP2022-10-11$5.65 RISE2022-12-28$2.40 PEAK2023-03-08$3.27 148d | -57.5% 78d | Missed | Missed | — | — | +36.3% 70d | Missed |
1–15 / 28 1 / 2 | |||||||
The United States market has experienced a positive trajectory, rising 1.8% over the last week and climbing 28% in the past year, with earnings projected to grow by 17% annually. In this favorable environment, growth stocks with strong insider ownership can be particularly attractive as they often indicate confidence from those closest to the company's operations and potential.
The United States market has shown robust performance, climbing 1.8% in the last 7 days and up 28% over the past year, with earnings forecasted to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly compelling as they often signal confidence from those who know the company best.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
Over the last 7 days, the United States market has risen 2.5%, contributing to a remarkable 26% climb over the past year, with earnings anticipated to grow by 17% per annum in the coming years. In this thriving environment, growth companies with high insider ownership are particularly noteworthy as they often demonstrate strong alignment between management and shareholder interests, potentially positioning them well for sustained success.
The United States market has shown robust performance with a 1.2% climb in the last week and a remarkable 29% increase over the past year, alongside expectations for earnings to grow by 17% annually in the coming years. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business's operations and potential.
The United States market has experienced a robust performance, with a 1.2% increase over the last week and a substantial 29% rise over the past year, while earnings are anticipated to grow by 17% annually in the coming years. In this environment, growth companies with significant insider ownership can be particularly appealing as they often align management interests with shareholder value and may indicate confidence in the company's future prospects.
Over the last 7 days, the United States market has risen by 1.1%, contributing to a notable 29% increase over the past year, with earnings anticipated to grow by 17% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business.
In the last week, the market has been flat, but over the past 12 months, it has risen by an impressive 27%, with earnings expected to grow by 17% per annum in the coming years. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong internal confidence and alignment of interests between shareholders and management.
The market has been flat in the last week but is up 27% over the past year, with earnings expected to grow by 17% annually in the coming years. In this context, growth companies with high insider ownership and significant revenue expansion can be particularly appealing as they often signal strong internal confidence and potential for sustained performance.
Abeona Therapeutics Inc (ABEO) reports robust revenue driven by ZevaSkin's launch, despite challenges in insurance approvals and rising expenses.
Abeona Therapeutics Inc. (ABEO) Q1 2026 Earnings Call May 13, 2026 8:30 AM EDTCompany ParticipantsJoseph Vazzano - Chief Financial OfficerVishwas Seshadri -...
Presentation Operator MessageOperator Good day, ladies and gentlemen, and welcome to the Abeona Therapeutics First Quarter 2026 Earnings Conference Call. [Operator instructions]. And please note,
Abeona Therapeutics (NASDAQ:ABEO) reported early commercial momentum for ZEVASKYN in the first quarter of 2026, with executives highlighting new patient treatments, expanded treatment-center activation and a newly licensed prostate cancer cell therapy program during the company’s earnings call. Chi
Q1 2026 Results and Pipeline Update May 13, 2026 Corporate Overview Vishwas Seshadri, Ph.D., M.B.A. CHIEF...
Abeona Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2026. For the first quarter, the company reported net loss was USD 17.08 million compared to USD 12.03 million...
Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
CLEVELAND — CLEVELAND — Abeona Therapeutics Inc. on Wednesday reported a loss of $17.1 million in its first quarter. The Cleveland-based company said it had a loss of 30 cents per share. ...
Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of $(0.24) per share from
Three patients treated with ZEVASKYN® in Q1 2026 - - QTC network expands to six sites, with two new additions on the East Coast - - In-licensed radically novel engineered T-cell technology with...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABEO | +6.45% | +14.23% | +9.68% | -7.37% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +3.48% | +19.94% | +13.12% | -20.06% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 957.3K | $4.29M | 0.00% | Added+6.6% | 2026-03-31 |
| FidelityFMR | fundamental | 194.8K | $872.76K | 0.00% | Added+15.6% | 2026-03-31 |
| RenTech | quant | 161.1K | $721.65K | 0.00% | Added+38.6% | 2026-03-31 |
| DEShaw | quant | 101.1K | $452.77K | 0.00% | Trimmed-4.6% | 2026-03-31 |
| TRowePrice | fundamental | 31.0K | $139 | 0.00% | Added+28.5% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | Alvino Mark | Director | G Gift | 500 | — | +$0 |
| 2026-05-22 | Alvino Mark | Director | S Open-market sale | 6,500 | $5.46 | −$35.5K |
| 2026-05-15 | Crombez Eric | Director | S Open-market sale | 26,143 | $5.53 | −$144.6K |
| 2026-05-11 | Vasanthavada Madhav | Chief Commercial Officer | S Open-market sale | 5,548 | $5.96 | −$33.1K |
| 2026-04-07 | Goldan Keith A. | Director | A Grant / award | 32,751 | — | +$0 |
| 2026-03-31 | Seshadri Vishwas | Chief Executive Officer | S Open-market sale | 29,985 | $4.38 | −$131.5K |
| 2026-03-16 | Vazzano Joseph Walter | Chief Financial Officer | S Open-market sale | 785 | $4.76 | −$3.7K |
| 2026-02-04 | Silverstein Christine Berni | Director | S Open-market sale | 20,070 | $5.09 | −$102.2K |
| 2026-02-02 | Alvino Mark | Director | S Open-market sale | 2,000 | $5.09 | −$10.2K |
| 2026-02-02 | Alland Leila | Director | S Open-market sale | 18,065 | $5.09 | −$92.0K |
| 2026-02-02 | Crombez Eric | Director | S Open-market sale | 16,284 | $5.09 | −$82.9K |
| 2026-02-02 | Wuchterl Donald A. | Director | S Open-market sale | 14,814 | $5.09 | −$75.4K |
| 2026-01-27 | Alland Leila | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Alvino Mark | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Charles Faith L. | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Amoroso Michael | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Silverstein Christine Berni | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Crombez Eric | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Zeiher Bernhardt G | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-27 | Wuchterl Donald A. | Director | A Grant / award | 37,313 | — | +$0 |
| 2026-01-26 | Vasanthavada Madhav | Chief Commercial Officer | S Open-market sale | 12,610 | $5.29 | −$66.7K |
| 2026-01-26 | Vasanthavada Madhav | Chief Commercial Officer | A Grant / award | 76,621 | — | +$0 |
| 2026-01-22 | O'Malley Brendan M. | SVP, Chief Legal Officer | S Open-market sale | 13,578 | $5.33 | −$72.4K |
| 2026-01-22 | Seshadri Vishwas | Chief Executive Officer | S Open-market sale | 69,832 | $5.33 | −$372.3K |
| 2026-01-22 | Vazzano Joseph Walter | Chief Financial Officer | S Open-market sale | 18,666 | $5.33 | −$99.5K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-13upcoming | -0.23 | — | — |
| 2026-05-13 | -0.39 | -0.30 | +23.73% |
| 2026-03-17 | -0.37 | -0.37 | +2.15% |
| 2025-11-12 | -0.34 | -0.11 | +68.54% |
| 2025-08-14 | -0.39 | -0.47 | -18.96% |
| 2025-05-15 | -0.35 | -0.24 | +32.20% |
| 2025-03-20 | -0.34 | -0.32 | +7.99% |
| 2024-11-14 | -0.39 | -0.63 | -63.21% |
| 2024-08-12 | -0.34 | -0.44 | -28.79% |
| 2024-05-15 | -0.53 | -0.52 | +1.38% |
| 2024-03-18 | -0.42 | -0.48 | -12.99% |
| 2023-11-13 | -0.54 | -0.43 | +19.83% |
| 2023-08-08 | -0.70 | -0.50 | +28.51% |
| 2023-05-11 | -0.58 | -0.67 | -15.98% |
| 2022-11-14 | -1.75 | -1.48 | +15.27% |
| 2022-08-11 | -0.67 | -2.08 | -208.15% |